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EDITORIAL COMMENT
Toward Understanding the
Evolution of Plaque Rupture
Correlating Vascular
Pathology With Clinical Outcomes*
James S. Forrester, MD, FACC
Los Angeles, California
Acute coronary syndromes are initiated by plaque rupture
(i.e., by the interaction between flowing blood and the
intimal surface). This interface is in continual flux over a
period of months. The blood vessel surface, very poorly
assessed by angiography (1,2), is best visualized by angios-
copy, which provides images most analogous to postmortem
gross anatomy. Unlike the postmortem, angioscopy can be
repeated over months and can be performed in symptomatic
living man. Thus, angioscopy first allowed us to discover
that patients with unstable angina have a disrupted intimal
surface (3,4). Now, serial angioscopic studies, such as that
by Sakai et al. (5) in this issue of the Journal, provide an
unparalleled opportunity to construct a framework for un-
derstanding the natural temporal evolution of plaque rup-
ture and how it is modified by therapy, thereby to better
understand and interpret both therapeutic alternatives and
clinical trial results.
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To begin to construct this framework, we can define the
initial presentation of myocardial infarction (MI). In con-
trast to angiography, angioscopy demonstrates thrombus in
essentially 100% of patients with atherosclerotic acute MI
(4,6). In contrast, unstable angina is more heterogeneous.
About 75% of patients have plaque rupture, and the throm-
bus is much more platelet-rich (seen angioscopically as
white thrombus) than the fibrin-rich with trapped red cells
(red thrombus) (6,7). This difference in clot composition
may explain the failure of thrombolytic therapy in unstable
angina (8).
The vascular pathology of plaque rupture is modified by
revascularization therapy. Even after restoration of Throm-
bolysis In Myocardial Infarction (TIMI) trial III angio-
graphic flow by successful thrombolysis in acute MI, how-
ever, the thrombus persists over at least a month after
therapy (9). Thus, in 56 patients studied between 24 h and
four weeks after MI, Van Belle et al. (10) found that
thrombolytic therapy reduced thrombus size, but that,
remarkably, there was no reduction in the number of
plaques containing thrombi. These data provide a potential
basis for understanding the 15% to 25% rate of reocclusion
following successful thrombolytic therapy. Conversely, an-
gioscopy has shown that thrombosis may be clinically and
angiographically silent. For instance, in 52 patients with
angiographically normal coronary artery segments, Alfonso
et al. (11) found plaque in 23 patients, flaps in 2, and
thrombus in 5.
In contrast to thrombolysis, percutaneous coronary inter-
vention (PCI) clearly has the potential to even more
powerfully alter the acutely ruptured plaque. We need first
to understand how angioplasty affects stable lesions. Balloon
angioplasty frequently induces angioscopically large surface
dissections that are undetected by angiography (12). For
instance, after percutaneous transluminal coronary angio-
plasty (PTCA), Kanamasa et al. (13) found disruptions in
17/35 and thrombi in 24/35 patients. The clinical relevance
of this observation is that post-PTCA abrupt closure is
predominantly due to dissection. Thus, in 17 patients with
acute postangioplasty occlusion, White et al. (14) found that
the primary cause of postangioplasty abrupt closure was
dissection in 14 patients (82%) and intracoronary thrombi in
3 others (18%). Angiography correctly identified the cause
of vessel occlusion in only 5 (29%) of these patients (14).
The lesions that are most prone to postprocedure cardiac
events most commonly have a thin fibrous cap and a large
lipid core (yellow plaques). Because these types of plaques
are also most prone to spontaneous rupture, they presum-
ably have a greater propensity to rupture and become
thrombogenic during angioplasty (15,16). In contrast to its
important role in abrupt closure, dissection does not corre-
late with restenosis, whereas postprocedure thrombus cor-
relates strongly (17).
With this background we can analyze the effect of
angioplasty in acute MI. Ueda et al. (18) found that,
although the frequency of thrombus persistence is less than
that observed after thrombolysis, the percentage remains
strikingly high, 64%, at one month. Thus, even with
restoration of apparently normal flow, there remains a
potent stimulus to rethrombosis, providing a biologic ratio-
nale for ongoing antiplatelet therapy.
By six months’ postangioplasty, however, thrombus is
detected in only 5% of patients, and the yellow color typical
of ruptured plaques evolves to the white surface that is
characteristic of stable lesions. From these observations we
may infer that intimal proliferation is active in the first six
months following angioplasty. On the clinical level, these
data provide a logical basis for assuming that both throm-
bogenic potential and the need for antithrombotic therapy
to prevent rethrombosis of the culprit lesion is low beyond
this point in time.
To evaluate the impact of stenting in acute MI, we must
again understand its effect on stable lesions. Sakatani et al.
(19) found that the rate of thrombus formation after
stenting was comparable to that following balloon angio-
plasty. Although some experimental results in animals have
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shown completion of neointimal coverage of stents in a few
weeks, this does not occur in human atherosclerotic lesions.
Thus, Ueda et al. (20) found that at 8 to 18 days after
stenting, no stent was covered by neointima. Later, at two to
four months, all stents were covered by neointima (20).
Although we might infer that the completion of neointimal
coverage of stents in human coronary arteries requires
approximately three months, others found only about 80%
of stents were covered at three months and that incomplete
neointimal coverage persisted at beyond six months in about
10% of patients (19). This percentage is likely to increase
with the latest generation of stents, because radiation and
drugs eluted from the stent surface may substantially inhibit
and delay stent re-endothelialization.
With this background we can now analyze what happens
when a lesion disrupted by plaque rupture is modified by
percutaneous intervention. Sakai et al. (5) recorded angio-
scopic images before and after balloon angioplasty and then
again after stent placement. Consistent with both prior
natural history and thrombolytic studies, all of the culprit
lesions had a protruding thrombus on a yellow plaque.
Balloon angioplasty reduced the mass of thrombus in about
two-thirds of the cases, but an intimal flap remained in
approximately 90%. Thus, although the vessel patency and
TIMI flow rate is markedly improved, the immediate effect
of balloon angioplasty on the blood vessel surface is not
much different from that of thrombolysis. The most striking
insight from the study by Sakai et al. (5) is the change in
vascular surface morphology after stenting. The stent com-
pressed the thrombus and covered the dissected surface,
eliminating both visually detectable thrombus and dissec-
tion in all cases. This initial difference provides a logical
basis for the findings of the widely quoted CADILLAC
trial in which patients treated by a stent plus abciximab had
a lower rate of combined death, reinfarction, disabling
stroke, and less repeat revascularization than did patients
treated by PTCA alone or by PTCA plus abciximab (21).
Conversely, it is clear that placement of a bare metallic
stent in a flowing blood stream clearly increases the risk of
thrombosis until it is re-endothelialized. From this study we
now know that, at one month, the stents are only partially
endothelialized and are covered with a thin lining of
thrombus. The lack of re-endothelialization of the stented
surface after MI, therefore, is similar to that seen in stable
lesions. The combination of lack of re-endothelialization
and the thin layer of thrombus also explains the high risk of
reocclusion in the first month following stenting in patients
not treated with antiplatelet agents, and fully justifies use of
these agents for the first few months after stenting (22).
By six months, however, about 95% of the stents were
covered with smooth white neointima. From these data we
can infer a second striking insight. At six months both the
rate of healing and the post-stent appearance does not seem
to be different from the previously reported observation of
stented stable plaques, which we know are often disrupted
by the angioplasty procedure itself. By six months, stented
stable and unstable lesions are essentially indistinguishable.
This result, then, explains why reinfarction at a site of prior
angioplasty is quite rare.
The return of 95% of stented culprit lesions to stability at
six months, however, also creates a clinical conundrum.
Clearly antiplatelet therapy for prevention of reocclusion at
Figure 1. Evolution of the ruptured plaque after revascularization. PTCA  percutaneous transluminal coronary angioplasty.
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the stented site might have little therapeutic role beyond six
months for the majority of patients. The parallel event
curves in clopidogrel-treated and -untreated patients in the
CURE trial after three to six months of therapy are
consistent with these data (23). In contrast, if we accept the
logical premise that failure to completely re-endothelialize
represents an ongoing prothrombotic risk, a small subgroup
of the stented infarct population remains at increased risk at
six months. Ironically, we have no method, other than
repeat angioscopy, to identify them. Thus, the question of
long duration of clopidogrel therapy post-stenting will
remain difficult, unless the drug is more clearly shown to
have a beneficial effect on atherosclerosis.
From these studies, we can construct a framework upon
which management of plaque rupture can be conceptualized
(Fig. 1). In atherosclerotic acute MI, a fibrin-rich thrombus
on a disrupted plaque is present, whether or not it is clearly
visualized by angiography. The lesion beneath the thrombus
is typically lipid-rich, with a thin fibrous cap. In contrast,
although unstable angina most commonly begins with
plaque rupture, the thrombus is nonocclusive and platelet-
rich. Following thrombolytic therapy in acute MI, the
natural history of thrombus evolution is slow, such that a
layer of thrombus persists on the healing surface at one
month. Beyond one month there is a gradual evolution
toward plaque stability. At three months the culprit lesion is
not fully healed: the culprit lesion remains ragged and
discolored. By six months, the lesion becomes smooth-
surfaced and has the appearance of a stable atheroma. This
natural history is modified by interventional procedures.
Although balloon angioplasty alone commonly restores
TIMI III flow, it does so by increasing lumen diameter and
reducing thrombus mass. Possibly because the torn surface
and thrombus remain, balloon angioplasty parallels throm-
bolytic therapy in plaque evolution. Thrombus is present at
one month, and the lesion becomes stable by six months.
In contrast, balloon angioplasty followed by stenting has
a different effect. The stent eliminates visible thrombus and
dissection. At one month, however, the stent is not endo-
thelialized, and it is often covered with a thin layer of
thrombus. As with the natural history of plaque evolution,
however, the stent surface gradually endothelializes. By six
months, 95% of the stents have a smooth intimal surface
characteristic of stable plaques. Perhaps 5% of stents retain
patchy areas that are not re-endothelialized. This frame-
work may prove useful in clinical trial design and interpre-
tation. Clearly, similar angioscopic studies will be of sub-
stantial value in understanding the local vascular response
after radiation therapy and implantation of the new gener-
ation of drug-eluting stents.
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